- Home
- ECOR vs ALRN Comparison
ECOR vs ALRN Comparison
Compare ECOR & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- ALRN
- Stock Information
- Founded
- ECOR 2005
- ALRN 2001
- Country
- ECOR United States
- ALRN United States
- Employees
- ECOR N/A
- ALRN N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- ECOR Health Care
- ALRN Health Care
- Exchange
- ECOR Nasdaq
- ALRN Nasdaq
- Market Cap
- ECOR 87.1M
- ALRN 76.9M
- IPO Year
- ECOR 2018
- ALRN 2017
- Fundamental
- Price
- ECOR $10.94
- ALRN $2.87
- Analyst Decision
- ECOR Strong Buy
- ALRN Strong Buy
- Analyst Count
- ECOR 1
- ALRN 1
- Target Price
- ECOR $15.00
- ALRN $19.00
- AVG Volume (30 Days)
- ECOR 157.1K
- ALRN 100.2K
- Earning Date
- ECOR 11-13-2024
- ALRN 11-14-2024
- Dividend Yield
- ECOR N/A
- ALRN N/A
- EPS Growth
- ECOR N/A
- ALRN N/A
- EPS
- ECOR N/A
- ALRN N/A
- Revenue
- ECOR $23,327,000.00
- ALRN N/A
- Revenue This Year
- ECOR $62.51
- ALRN N/A
- Revenue Next Year
- ECOR $31.32
- ALRN N/A
- P/E Ratio
- ECOR N/A
- ALRN N/A
- Revenue Growth
- ECOR 74.10
- ALRN N/A
- 52 Week Low
- ECOR $5.02
- ALRN $1.61
- 52 Week High
- ECOR $14.20
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- ECOR 49.51
- ALRN 33.51
- Support Level
- ECOR $10.40
- ALRN $3.46
- Resistance Level
- ECOR $14.20
- ALRN $3.92
- Average True Range (ATR)
- ECOR 1.25
- ALRN 0.40
- MACD
- ECOR -0.14
- ALRN -0.12
- Stochastic Oscillator
- ECOR 14.21
- ALRN 11.56
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.